NEW YORK, Jan. 17, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on DSS, IDXG, ITUS, and MARA which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com presents for review: Document Security Systems Inc. (NYSE AMER: DSS), Interpace Diagnostics Group Inc. (NASDAQ: IDXG), ITUS Corp. (NASDAQ: ITUS), and Marathon Patent Group Inc. (NASDAQ: MARA). These stocks are a part of the Business Services sector, which comprises of companies that provide ancillary services to other players in the market. Hence, the core business of one company can be a business service for another. All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Document Security Systems
Rochester, New York headquartered Document Security Systems Inc.'s stock finished Tuesday's session 3.29% higher at $2.20. A total volume of 1.04 million shares was traded, which was above their three months average volume of 580,120 shares. The Company's shares have surged 73.23% in the past month, 175.00% over the previous three months, and 178.48% over the past year. The stock is trading above its 50-day and 200-day moving averages by 65.76% and 127.25%, respectively. Furthermore, shares of the Company, which through its subsidiaries, develops, manufactures, markets, and sells paper and plastic products to protect information from unauthorized scanning, copying, and digital imaging worldwide, have a Relative Strength Index (RSI) of 61.68. Get the full research report on DSS for free by clicking below at:
www.wallstequities.com/registration/?symbol=DSS
Interpace Diagnostics Group
Shares in Parsippany, New Jersey headquartered Interpace Diagnostics Group Inc. ended at $1.10, down 4.26% from the last trading session. The stock recorded a trading volume of 932,444 shares, which was above its three months average volume of 925,160 shares. The Company's shares have gained 15.79% in the last month. The stock is trading 0.61% above its 50-day moving average. Moreover, shares of Interpace Diagnostics, which develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers, have an RSI of 52.20. Free research on IDXG can be accessed at:
www.wallstequities.com/registration/?symbol=IDXG
ITUS Corp.
Los Angeles, California-based ITUS Corp.'s stock ended yesterday's session 8.89% higher at $4.41. A total volume of 2.37 million shares was traded, which was above their three months average volume of 668,150 shares. The Company's shares have advanced 70.27% in the past month and 38.24% over the previous three months. The stock is trading 64.83% and 149.45% above its 50-day and 200-day moving averages, respectively. Additionally, shares of ITUS Corp., which funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology, have an RSI of 84.96. Sign up today for the free research report on ITUS at:
www.wallstequities.com/registration/?symbol=ITUS
Marathon Patent Group
On Tuesday, shares in Los Angeles, California headquartered Marathon Patent Group Inc. recorded a trading volume of 2.54 million shares. The stock finished 13.91% lower at $3.59. The Company's shares have skyrocketed 124.37% in the previous three months. The stock is trading above its 200-day moving average by 69.20%. Furthermore, shares of Marathon Patent, which together with its subsidiaries, acquires and monetizes patents primarily in the US, have an RSI of 45.32. Wall St. Equities' research coverage also includes the downloadable free report on MARA at:
www.wallstequities.com/registration/?symbol=MARA
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-business-services-equities----document-security-systems-interpace-diagnostics-itus-and-marathon-patent-300583821.html
SOURCE Wall St. Equities
